Twenty years ago, Meryl Streep gave us Miranda Priestly, the ruthlessly perfect editor ruling a pristine print empire. This year, the cast returned in a sequel that lands with uncanny timing. Miranda now faces an existential threat to her legacy: a digital media landscape rearranging itself, and an AI-driven world that no longer waits for her cover decisions. She cannot rely on the old ways. She must adapt, or face irrelevance.
Then, Miranda taught us a quieter truth about how industries actually change. The cerulean sweater we think we chose was decided for us years earlier, in a room we'll never enter. The people at the top of a system shape what everyone else ends up wearing, whether they notice or not.
Watching this unfold, I couldn't help but see a striking parallel in our own world of life sciences and clinical research. Just like the fashion and media industry, clinical trials are undergoing a generational metamorphosis, driven not just by digital formats but by the relentless, transformative power of AI. And just as Miranda must make peace with a new reality, sponsors, CROs, and sites must now befriend AI to keep pace with the FDA's groundbreaking announcement on April 28, 2026: Real-time clinical trial (RTCT).
The 2006 shift: From paper mountains to digital landscapes
Rewind two decades. When the original Devil Wears Prada hit theaters in 2006, our industry was grappling with its own monumental shift: the painful but necessary transition from paper to digital. We ran on mountains of paper case report forms (CRFs) and double-key data entry. The FDA was enforcing 21 CFR Part 11, laying the groundwork for electronic records and signatures. Moving to electronic data capture (EDC) and clinical trial management systems (CTMS) felt revolutionary and daunting.
There was widespread fear of losing the tangible "source" paper trail. Yet, we adapted. We digitized our workflows, and the industry became faster and more efficient.
That was just the prologue.
The 2026 reality: Befriending AI and real-time data
The FDA has done this before. In 1962, after the thalidomide tragedy, the Kefauver-Harris Amendment rewrote what "evidence" meant, proof of efficacy, not just safety. The phased clinical trial system we still use is a direct descendant of that decision. The agency is doing it again now, this time deciding that data submitted at the end is no longer the only definition of submission.
Today, our industry is moving beyond static end-of-trial data. The FDA has launched a request for information (RFI) for RTCTs. Departing from the framework that has shaped drug development since 1962, the agency is testing an AI-enabled continuous monitoring system rather than retrospective review, aimed at accelerating drug development, reducing delays, and closing the gaps between trial phases. Proof-of-concept trials at AstraZeneca and Amgen are already streaming safety signals and endpoints to the agency in real time.
This is a fundamental paradigm shift. The lag between data collection and regulatory review, a gap that historically delayed life-saving therapies, is being aggressively minimized.
The risks and opportunities of relinquishing control
In the sequel, Miranda faces the terrifying prospect of losing absolute control over her brand's narrative. For sponsors, the FDA's push for real-time data presents a very similar fear.
The risks
Historically, sponsors have enjoyed the ability to carefully curate, clean, and analyze data before wrapping it up with a bow for the FDA. Real-time access means less control over data curation. It demands flawless, continuous data integrity, as regulators will see safety signals and anomalies exactly when the sponsors do. There is no longer a buffer zone to polish the narrative perfectly.
The opportunities
However, just as adaptation is the key to survival, this transparency unlocks massive opportunities. Real-time data sharing powered by AI allows for:
Faster protocol adjustments
If a safety signal or efficacy trend is spotted early, trial protocols can be adapted mid-flight, saving time and resources.
Continuous trials
The traditional "hiatus" between phase 1, 2, and 3 trials could be eliminated, allowing for a seamless, continuous development lifecycle.
Accelerated approvals
Ultimately, giving the FDA continuous access to the under-the-hood view builds regulatory trust and can significantly speed up the approval of critical therapies.
The girl next door: From assistant to co-reviewer
There is a quieter parallel worth naming. In the 2006 version, the sassy Emily was the assistant. In 2026, she is the competitor. AI, too, used to be the vendor tool you bought to clean up adverse event coding. In 2026, it is the co-reviewer sitting on the regulator's side of the table, reading your data before your medical monitor does. The thing you trained is now grading you.
The regulator is wrestling with the same governance questions you are. The FDA commissioner has publicly acknowledged that the agency's own internal AI tool, Elsa, can hallucinate. That admission cuts both ways. It signals openness about AI's limits, but it also means the FDA now knows exactly what to ask sponsors about their AI. Your governance story, including model validation, human-in-the-loop review, and audit trails for every AI-assisted decision, cannot be vaguer than the regulator's. If the FDA has thought harder about its AI than you have about yours, you have a problem.
Redefining our industry
"That's all," Miranda Priestly would famously say to dismiss her assistants. But for us, this is just the beginning.
The transition from paper to digital two decades ago prepared us for the speed of modern research. Now, the transition from episodic digital reporting to continuous, AI-driven real-time data will redefine it entirely. The FDA's new guidance is a clear signal: the days of delayed data submissions are numbered. As industry leaders, we cannot afford to fight this shift. Like Meryl Streep's iconic character, we must evolve, embrace the discomfort of transparency, and befriend AI to write the next chapter of life sciences innovation.
Another key observation hiding in plain sight is that, similar to the fashion world, where the world revolves around big brands, in the regulated life sciences world, big companies have an upper hand in defining this pivotal transition. It is not a coincidence that six companies under consideration for a proof-of-concept trial for RTCT are among the top 20 global biopharma organizations. What is obviously missing from this RFI is the voice of emerging biotech. The reality today is that the bulk of innovation and disruption is now driven by small and emerging biotech, and it is imperative for the success of RTCT that the FDA finds a way to involve smaller players in this RFI.
Our industry spent the last 20 years digitizing processes and moving away from the blockbuster model. The next 20 will focus on digitizing judgment and transforming the clinical process to align with specialty and rare-disease therapies.